Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the safety and effectiveness of an investigational
drug (AV608) when used in subjects who have Social Anxiety Disorder. AV608 is an NK-1
receptor antagonist that exhibits central nervous system activity after oral administration.
The study will compare AV608 to placebo (a medically inactive substance) to see if AV608
helps the symptoms of Social Anxiety Disorder. Eligible subjects will be assigned by chance
to take either AV608 or placebo for 12 weeks. During the study, subjects will be asked about
their overall health and mood and their Social Anxiety Disorder.